Breaking the Vicious Circle of AMD Progression with Oxidation-Resistant DHA

Time: 12:00 pm
day: Track 1 Day 2 AM


  • Explore how retinal OSE proliferation can turn the idling alternative complement pathway into a pathologic response as demonstrated by the impaired ability of the Factor H AMD risk variant CFH 402H to neutralize retinal OSEs
  • Examine a custom-designed allylic deuteriumreinforced analogue of DHA (D-DHA) which represents a novel approach to preventing retinal LPO and its downstream effects on AMD progression
  • Discuss the specific advantages of D-DHA for treating dry AMD (oral delivery, preclinical safety, target engagement and pleiotropic mechanism of action)